Patents by Inventor Govert Johan Schouten
Govert Johan Schouten has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9878034Abstract: The invention relates to adjuvanted vaccine formulations, in particular influenza vaccines for intranasal delivery. Provided is an adjuvanted influenza vaccine formulation, comprising (i) peptidoglycan microparticles obtained from a Gram-positive bacterium and (ii) at least one influenza virus antigen or antigenic preparation thereof, which antigen or antigenic preparation is not fused or otherwise covalently attached to a proteinaceous peptidoglycan binding moiety.Type: GrantFiled: October 1, 2010Date of Patent: January 30, 2018Assignee: MUCOSIS B.V.Inventors: Govert Johan Schouten, Cornelis Johannes Leenhouts
-
Publication number: 20120219586Abstract: The invention relates to adjuvanted vaccine formulations, in particular influenza vaccines for intranasal delivery. Provided is an adjuvanted influenza vaccine formulation, comprising (i) peptidoglycan microparticles obtained from a Gram-positive bacterium and (ii) at least one influenza virus antigen or antigenic preparation thereof, which antigen or antigenic preparation is not fused or otherwise covalently attached to a proteinaceous peptidoglycan binding moiety.Type: ApplicationFiled: October 1, 2010Publication date: August 30, 2012Inventors: Govert Johan Schouten, Cornelis Johannes Leenhouts
-
Publication number: 20110044982Abstract: The invention relates to the field of immunology and vaccines. In particular, it relates to proteinaceous substances and the uses thereof in vaccines against infections caused by respiratory pathogens.Type: ApplicationFiled: September 22, 2009Publication date: February 24, 2011Inventors: Cornelis Johannes Leenhouts, Maarten Leonardus van Roosmalen, Govert Johan Schouten
-
Patent number: 7527961Abstract: Means and methods for producing mammalian viruses, the method comprising infecting a culture of immortalized human cells with a virus, incubating the culture infected with virus to propagate the virus under conditions that permit growth of the virus, and to form a virus-containing medium, and removing the virus-containing medium. The viruses can be harvested and be used for the production of vaccines. Advantages include that human cells of the present invention can be cultured under defined serum-free conditions and the cells show improved capability for propagating virus. Methods are provided for producing, in cultured human cells, influenza virus and vaccines derived thereof. This method eliminates the necessity of using whole chicken embryos for the production of Influenza vaccines. The method also provides for the continuous or batch-wise removal of culture media. As such, the present invention allows the large-scale continuous production of viruses to a high titer.Type: GrantFiled: November 11, 2005Date of Patent: May 5, 2009Assignee: Crucell Holland B.V.Inventors: Maria Grazia Pau, Alphonsus G. C. M. UytdeHaag, Govert Johan Schouten
-
Patent number: 7491532Abstract: Methods and compositions for the production of recombinant proteins in a eukaryotic cell line are disclosed. The methods and compositions are particularly useful for generating stable expression of recombinant proteins of interest that are modified post-translationally, for example, by glycosylation. Such proteins may have advantageous properties in comparison with their counterparts produced in non-human systems such as Chinese hamster ovary cells.Type: GrantFiled: March 1, 2004Date of Patent: February 17, 2009Assignee: Crucell Holland, B.V.Inventors: Abraham Bout, Guus Hateboer, Karina Cornelia Verhulst, Alphonsus Gerardus Uytdehaag, Govert Johan Schouten
-
Publication number: 20090017068Abstract: Described are vaccines containing (whole-inactivated) West Nile Viruses and/or West Nile viral proteins derived therefrom, produced on human cells, wherein the human cells comprise a sequence encoding at least one early region-1 (E1) gene product of an adenovirus. The cells are preferably cultured in suspension to very high densities and under serum-free conditions. Herein, it is disclosed that use of such cells results in high titers of West Nile Virus produced.Type: ApplicationFiled: July 29, 2008Publication date: January 15, 2009Applicant: Crucell Holland B.V.Inventors: Alphonsus G.C.M. UytdeHaag, Govert Johan Schouten, Jaap Goudsmit
-
Publication number: 20080274497Abstract: Methods and compositions for the production of recombinant proteins in a eukaryotic cell line are disclosed. The methods and compositions are particularly useful for generating stable expression of recombinant proteins of interest that are modified post-translationally, for example, by glycosylation. Such proteins may have advantageous properties in comparison with their counterparts produced in non-human systems such as Chinese hamster ovary cells.Type: ApplicationFiled: March 1, 2004Publication date: November 6, 2008Inventors: Abraham Bout, Guus Hateboer, Karina Cornelia Verhulst, Alphonsus Gerardus Uytdehaag, Govert Johan Schouten
-
Patent number: 7425437Abstract: The present invention relates to novel vaccines containing (whole-inactivated) West Nile Viruses and/or West Nile viral proteins derived therefrom, produced on human cells, wherein the human cells comprise a sequence encoding at least one early region-1 (E1) gene product of an adenovirus. The cells are preferably cultured in suspension to very high densities and under serum-free conditions. Herein, it is disclosed that use of such cells results in high titers of West Nile Virus produced.Type: GrantFiled: April 20, 2005Date of Patent: September 16, 2008Assignee: Crucell Holland B.V.Inventors: Alphonsus G. C. M. UytdeHaag, Govert Johan Schouten, Jaap Goudsmit
-
Patent number: 7238528Abstract: The invention provides a nucleic acid delivery vehicle with or having been provided with at least a tissue tropism for fibroblast-like or macrophage-like cells, preferably synoviocytes. In one aspect, the nucleic acid delivery vehicle is a virus capsid or a functional part, derivative and/or analogue thereof. Preferably, the virus capsid is an adenovirus capsid. Preferably, the adenovirus is a subgroup B adenovirus, such as adenovirus 16. Preferably, the tissue tropism is provided by at least a tissue tropism determining part of an adenovirus fiber protein or a functional derivative and/or analogue thereof. The invention further presents methods for the treatment of diseases, such as joint related diseases.Type: GrantFiled: February 20, 2004Date of Patent: July 3, 2007Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Govert Johan Schouten, Abraham Bout, Menzo Jans Emco Havenga
-
Patent number: 7163787Abstract: The present invention provides novel methods for determining whether a compound influences a phase in the life cycle of a virus comprising providing a cell with the compound and with at least a fragment of the virus sufficient for performing the phase and determining whether the phase is influenced in the cell, the cell comprising a nucleic acid encoding an adenovirus early protein or a functional part, derivative and/or analogue of the adenovirus early protein. In another aspect, the invention provides the use of a cell, the cell comprising nucleic acid encoding an adenovirus early protein, for screening a library of compounds for the presence of a compound capable of influencing a phase in the life cycle of a virus capable of entering the cell.Type: GrantFiled: October 30, 2003Date of Patent: January 16, 2007Assignee: Crucell Holland B.V.Inventors: Ronald H. P. Brus, Govert Johan Schouten, Alphonsus G. C. M. UytdeHaag
-
Patent number: 7132280Abstract: Methods and compositions for the production of recombinant proteins in a human cell line. The methods and compositions are particularly useful for generating stable expression of human recombinant proteins of interest that are modified post-translationally, for example, by glycosylation. Such proteins may have advantageous properties in comparison with their counterparts produced in non-human systems such as Chinese hamster ovary cells.Type: GrantFiled: September 3, 2002Date of Patent: November 7, 2006Assignee: Crucell Holland, B.V.Inventors: Abraham Bout, Guus Hateboer, Karina Cornelia Verhulst, Alphonsus Gerardus Uytdehaag, Govert Johan Schouten
-
Patent number: 6855544Abstract: Methods and compositions for the production of recombinant proteins in a human cell line. The methods and positions are particularly useful for generating stable expression of human recombinant proteins of interest that are modified post-translationally, for example, by glycosylation. Such proteins may have advantageous properties in comparison with their counterparts produced in non-human systems such as Chinese Hamster Ovary cells.Type: GrantFiled: April 14, 2000Date of Patent: February 15, 2005Assignee: Crucell Holland B.V.Inventors: Guus Hateboer, Karina Cornelia Verhulst, Govert Johan Schouten, Alphonsus Gerardus Uytdehaag, Abraham Bout
-
Publication number: 20040142473Abstract: The invention provides a nucleic acid delivery vehicle with or having been provided with at least a tissue tropism for fibroblast-like or macrophage-like cells, preferably synoviocytes. In one aspect, the nucleic acid delivery vehicle is a virus capsid or a functional part, derivative and/or analogue thereof. Preferably, the virus capsid is an adenovirus capsid. Preferably, the adenovirus is a subgroup B adenovirus, such as adenovirus 16. Preferably, the tissue tropism is provided by at least a tissue tropism determining part of an adenovirus fiber protein or a functional derivative and/or analogue thereof. The invention further presents methods for the treatment of diseases, such as joint related diseases.Type: ApplicationFiled: February 20, 2004Publication date: July 22, 2004Inventors: Ronald Vogels, Govert Johan Schouten, Abraham Bout
-
Publication number: 20040086850Abstract: The present invention provides novel methods for determining whether a compound influences a phase in the life cycle of a virus comprising providing a cell with the compound and with at least a fragment of the virus sufficient for performing the phase and determining whether the phase is influenced in the cell, the cell comprising a nucleic acid encoding an adenovirus early protein or a functional part, derivative and/or analogue of the adenovirus early protein. In another aspect, the invention provides the use of a cell, the cell comprising nucleic acid encoding an adenovirus early protein, for screening a library of compounds for the presence of a compound capable of influencing a phase in the life cycle of a virus capable of entering the cell.Type: ApplicationFiled: October 30, 2003Publication date: May 6, 2004Applicant: Crucell Holland B.V.Inventors: Ronald H.P. Brus, Govert Johan Schouten, Alphonsus G.C.M. UytdeHaag
-
Publication number: 20030092160Abstract: Methods and compositions for the production of recombinant proteins in a human cell line. The methods and compositions are particularly useful for generating stable expression of human recombinant proteins of interest that are modified post-translationally, for example, by glycosylation. Such proteins may have advantageous properties in comparison with their counterparts produced in non-human systems such as Chinese hamster ovary cells.Type: ApplicationFiled: September 3, 2002Publication date: May 15, 2003Inventors: Abraham Bout, Guus Hateboer, Karina Cornelia Verhulst, Alphonsus Gerardus Uytdehaag, Govert Johan Schouten
-
Publication number: 20030073659Abstract: Chimeric viral vectors having both the capacity to infect host cells efficiently and the capacity to integrate their genomic material into the host cell's genome. A chimeric viral vector having a functional packaging signal derived from a first virus and an integration means derived from a second virus. Typically, viruses capable of integrating their material into a host cell genome, having additional genetic material introduced therein recombinantly, do not have much room for insertion of such additional genetic material or are not very well capable of infecting every wanted host cell. Infecting viruses also lack a high insertion capacity or integration into the host cell's genome. The present invention provides integration of large inserts into a host cell's genome at an efficient infection rate by combining the properties of efficiently infecting viruses with efficiently integrating viruses.Type: ApplicationFiled: July 15, 2002Publication date: April 17, 2003Inventors: Markus Peter Einerhand, Domenico Valerio, Govert Johan Schouten
-
Patent number: 6468771Abstract: The present invention provides chimeric viral vectors which have both the capacity to infect host cells efficiently and the capacity to integrate their genomic material into the host cell's genome. The invention provides a chimeric viral vector which comprises a functional packaging signal derived from a first virus and an integration derived from a second virus. Typically, viruses capable of integrating their material into a host cell genome, having additional genetic material introduced therein by recombinant process, do not have much room for insertion of such additional genetic material or are not very well capable of infecting every wanted host cell. Infecting viruses also lack a high insertion capacity or integration into the host cell's genome. The present invention provides integration of large inserts into a host cell's genome at an efficient infection rate by combining the properties of efficiently infecting viruses with efficiently integrating viruses.Type: GrantFiled: June 23, 2000Date of Patent: October 22, 2002Assignee: IntrogeneInventors: Markus Peter Einerhand, Domenico Valerio, Govert Johan Schouten
-
Patent number: 6051430Abstract: The present invention provides novel elements for improving genetic engineering techniques for producing recombinant nucleic acid molecules and/or recombinant cells. The novel elements are capable of integrating desired nucleic acid material into other nucleic acid materials, specifically into the genome of a host cell. The novel elements are derived from or based on transposons, in particular from the Tc/Mariner superfamily. In particular, the essential elements of Tc1 enabling excision and pasting of the desired nucleic acid material are provided, together with the relevant transposase activity in cis or in trans.Type: GrantFiled: May 7, 1999Date of Patent: April 18, 2000Assignees: Het Nederlands Kanker Instituut, IntroGene B.V.Inventors: Ronald Hans Anton Plasterk, Domenico Valerio, Govert Johan Schouten, Hendricus Gerhard Adrianus Maria van Luenen, Jan C. Vos